BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 32492752)

  • 21. Oral pyogenic granulomas show MAPK/ERK signaling pathway activation, which occurs independently of BRAF, KRAS, HRAS, NRAS, GNA11, and GNA14 mutations.
    Pereira TDSF; de Amorim LSD; Pereira NB; Vitório JG; Duarte-Andrade FF; Guimarães LM; Diniz MG; Gomes CC; Gomez RS
    J Oral Pathol Med; 2019 Nov; 48(10):906-910. PubMed ID: 31310691
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Brown tumors of the jaws associated with primary or secondary hyperparathyroidism. A clinical study and review of the literature.
    Triantafillidou K; Zouloumis L; Karakinaris G; Kalimeras E; Iordanidis F
    Am J Otolaryngol; 2006; 27(4):281-6. PubMed ID: 16798410
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Association of KRAS G13D tumor mutations with outcome in patients with metastatic colorectal cancer treated with first-line chemotherapy with or without cetuximab.
    Tejpar S; Celik I; Schlichting M; Sartorius U; Bokemeyer C; Van Cutsem E
    J Clin Oncol; 2012 Oct; 30(29):3570-7. PubMed ID: 22734028
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Activation of MEK1/2-ERK1/2 signaling during NNK-induced lung carcinogenesis in female A/J mice.
    Yamakawa K; Yokohira M; Nakano Y; Kishi S; Kanie S; Imaida K
    Cancer Med; 2016 May; 5(5):903-13. PubMed ID: 26864819
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Loss of Somatostatin Receptor Subtype 2 Promotes Growth of KRAS-Induced Pancreatic Tumors in Mice by Activating PI3K Signaling and Overexpression of CXCL16.
    Chalabi-Dchar M; Cassant-Sourdy S; Duluc C; Fanjul M; Lulka H; Samain R; Roche C; Breibach F; Delisle MB; Poupot M; Dufresne M; Shimaoka T; Yonehara S; Mathonnet M; Pyronnet S; Bousquet C
    Gastroenterology; 2015 Jun; 148(7):1452-65. PubMed ID: 25683115
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Common and mutation specific phenotypes of KRAS and BRAF mutations in colorectal cancer cells revealed by integrative -omics analysis.
    Kundu S; Ali MA; Handin N; Conway LP; Rendo V; Artursson P; He L; Globisch D; Sjöblom T
    J Exp Clin Cancer Res; 2021 Jul; 40(1):225. PubMed ID: 34233735
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical characteristics and prognostic value of the
    Yuan Y; Liu Y; Wu Y; Zhang J; Shen C; Zhang F; Wu C; Hu W
    Int J Biol Markers; 2021 Jun; 36(2):33-39. PubMed ID: 34044655
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Brown tumor of the jaw as a rare manifestation of hyperparathyroidism: Two case reports and literature review.
    Hakkou F; Benjelloun L; Hallab L; Chbicheb S
    Int J Surg Case Rep; 2023 Oct; 111():108823. PubMed ID: 37725859
    [TBL] [Abstract][Full Text] [Related]  

  • 29.
    Coupez D; Hulo P; Touchefeu Y; Denis MG; Bennouna J
    Expert Opin Biol Ther; 2021 Oct; 21(10):1325-1334. PubMed ID: 34378483
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Outcome according to KRAS-, NRAS- and BRAF-mutation as well as KRAS mutation variants: pooled analysis of five randomized trials in metastatic colorectal cancer by the AIO colorectal cancer study group.
    Modest DP; Ricard I; Heinemann V; Hegewisch-Becker S; Schmiegel W; Porschen R; Stintzing S; Graeven U; Arnold D; von Weikersthal LF; Giessen-Jung C; Stahler A; Schmoll HJ; Jung A; Kirchner T; Tannapfel A; Reinacher-Schick A
    Ann Oncol; 2016 Sep; 27(9):1746-53. PubMed ID: 27358379
    [TBL] [Abstract][Full Text] [Related]  

  • 31. KRAS G12D or G12V Mutation in Human Brain Arteriovenous Malformations.
    Oka M; Kushamae M; Aoki T; Yamaguchi T; Kitazato K; Abekura Y; Kawamata T; Mizutani T; Miyamoto S; Takagi Y
    World Neurosurg; 2019 Jun; 126():e1365-e1373. PubMed ID: 30902772
    [TBL] [Abstract][Full Text] [Related]  

  • 32. BRAF V600E mutation and KRAS codon 13 mutations predict poor survival in Chinese colorectal cancer patients.
    Chen J; Guo F; Shi X; Zhang L; Zhang A; Jin H; He Y
    BMC Cancer; 2014 Nov; 14():802. PubMed ID: 25367198
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A Novel Mutation in a Patient with Hyperparathyroidism-Jaw Tumour Syndrome.
    Bellido V; Larrañaga I; Guimón M; Martinez-Conde R; Eguia A; Perez de Nanclares G; Castaño L; Gaztambide S
    Endocr Pathol; 2016 Jun; 27(2):142-6. PubMed ID: 26995009
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Molecular spectrum of KRAS, BRAF, and PIK3CA gene mutation: determination of frequency, distribution pattern in Indian colorectal carcinoma.
    Bisht S; Ahmad F; Sawaimoon S; Bhatia S; Das BR
    Med Oncol; 2014 Sep; 31(9):124. PubMed ID: 25073438
    [TBL] [Abstract][Full Text] [Related]  

  • 35. KRAS
    Zhou ZW; Ambrogio C; Bera AK; Li Q; Li XX; Li L; Son J; Gondi S; Li J; Campbell E; Jin H; Okoro JJ; Xu CX; Janne PA; Westover KD
    Cancer Res; 2020 Sep; 80(17):3719-3731. PubMed ID: 32605999
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Characterization of rare transforming KRAS mutations in sporadic colorectal cancer.
    Tong JH; Lung RW; Sin FM; Law PP; Kang W; Chan AW; Ma BB; Mak TW; Ng SS; To KF
    Cancer Biol Ther; 2014 Jun; 15(6):768-76. PubMed ID: 24642870
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Multipoint Kras oncogene mutations potentially indicate mucinous carcinoma on the entire spectrum of mucinous ovarian neoplasms.
    Lee YJ; Lee MY; Ruan A; Chen CK; Liu HP; Wang CJ; Chao WR; Han CP
    Oncotarget; 2016 Dec; 7(50):82097-82103. PubMed ID: 27888800
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Analysis of KRAS and BRAF genes mutation in the central nervous system metastases of non-small cell lung cancer.
    Nicoś M; Krawczyk P; Jarosz B; Sawicki M; Szumiłło J; Trojanowski T; Milanowski J
    Clin Exp Med; 2016 May; 16(2):169-76. PubMed ID: 25902737
    [TBL] [Abstract][Full Text] [Related]  

  • 39. 4-Acetyl-Antroquinonol B Improves the Sensitization of Cetuximab on Both Kras Mutant and Wild Type Colorectal Cancer by Modulating the Expression of Ras/Raf/miR-193a-3p Signaling Axis.
    Chu YC; Tsai TY; Yadav VK; Deng L; Huang CC; Tzeng YM; Yeh CT; Chen MY
    Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299137
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The proprotein convertase furin is a pro-oncogenic driver in KRAS and BRAF driven colorectal cancer.
    He Z; Thorrez L; Siegfried G; Meulemans S; Evrard S; Tejpar S; Khatib AM; Creemers JWM
    Oncogene; 2020 Apr; 39(17):3571-3587. PubMed ID: 32139876
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.